Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
370 GBX | +1.37% | 0.00% | +4.96% |
May. 22 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
May. 22 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
Financials (USD)
Sales 2024 * | 36.42M | Sales 2025 * | 46.63M | Capitalization | 492M |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | -45M | EV / Sales 2024 * | 9.41 x |
Net cash position 2024 * | 150M | Net cash position 2025 * | 120M | EV / Sales 2025 * | 7.98 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-11.2
x | Employees | 143 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.86% |
Latest transcript on MaxCyte, Inc.
1 day | +1.37% | ||
1 month | -6.33% | ||
3 months | +17.46% | ||
6 months | -5.73% | ||
Current year | +4.96% |
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 23-03-26 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 22-11-30 |
Art Mandell
BRD | Director/Board Member | 71 | 06-04-30 |
Will Brooke
BRD | Director/Board Member | 68 | 04-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.20% | 12 M€ | -.--% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 370 | +1.37% | 17,517 |
24-06-06 | 365 | +4.29% | 42,514 |
24-06-05 | 350 | +1.45% | 15,650 |
24-06-04 | 345 | -3.36% | 5,010 |
24-06-03 | 357 | -3.51% | 12,553 |
Delayed Quote London S.E., June 07, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.96% | 492M | |
+9.48% | 222B | |
+13.72% | 195B | |
+23.79% | 148B | |
+33.39% | 113B | |
+4.75% | 66.45B | |
+3.16% | 50.03B | |
-4.35% | 38.8B | |
-1.27% | 34.85B | |
+22.61% | 30.98B |
- Stock Market
- Equities
- MXCT Stock